PL4294395T3 - Leczenie raka sutka za pomocą terapii skojarzonych zawierających GDC-9545 i GDC-0077 - Google Patents

Leczenie raka sutka za pomocą terapii skojarzonych zawierających GDC-9545 i GDC-0077

Info

Publication number
PL4294395T3
PL4294395T3 PL22713478.0T PL22713478T PL4294395T3 PL 4294395 T3 PL4294395 T3 PL 4294395T3 PL 22713478 T PL22713478 T PL 22713478T PL 4294395 T3 PL4294395 T3 PL 4294395T3
Authority
PL
Poland
Prior art keywords
gdc
treatment
breast cancer
combination therapies
therapies
Prior art date
Application number
PL22713478.0T
Other languages
English (en)
Polish (pl)
Inventor
Ciara METCALFE
Xiaojing Wang
Wei Zhou
Original Assignee
Genentech, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=80953424&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL4294395(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech, Inc. filed Critical Genentech, Inc.
Publication of PL4294395T3 publication Critical patent/PL4294395T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
PL22713478.0T 2021-02-16 2022-02-14 Leczenie raka sutka za pomocą terapii skojarzonych zawierających GDC-9545 i GDC-0077 PL4294395T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163149944P 2021-02-16 2021-02-16
PCT/US2022/016270 WO2022177844A1 (en) 2021-02-16 2022-02-14 Treatment of breast cancer using combination therapies comprising gdc-9545 and gdc-0077

Publications (1)

Publication Number Publication Date
PL4294395T3 true PL4294395T3 (pl) 2025-06-23

Family

ID=80953424

Family Applications (1)

Application Number Title Priority Date Filing Date
PL22713478.0T PL4294395T3 (pl) 2021-02-16 2022-02-14 Leczenie raka sutka za pomocą terapii skojarzonych zawierających GDC-9545 i GDC-0077

Country Status (8)

Country Link
US (1) US20230381155A1 (https=)
EP (1) EP4294395B1 (https=)
JP (1) JP2024506385A (https=)
CN (1) CN117377472A (https=)
ES (1) ES3030540T3 (https=)
PL (1) PL4294395T3 (https=)
TW (1) TWI808648B (https=)
WO (1) WO2022177844A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025163068A (ja) * 2022-11-02 2025-10-28 ペトラ・ファーマ・コーポレイション 疾患の治療のためのホスホイノシチド３－キナーゼ（ｐｉ３ｋ）のアロステリックポケット及びオルソステリックポケットの標的化
KR20250107982A (ko) * 2022-11-02 2025-07-14 페트라 파마 코포레이션 질환의 치료를 위한 포스포이노시티드 3-키나제 (pi3k)의 알로스테릭 및 오르토스테릭 포켓 표적화

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102785474B1 (ko) 2014-12-18 2025-03-26 에프. 호프만-라 로슈 아게 테트라하이드로-피리도[3,4-b]인돌 에스트로겐 수용체 조절제 및 이의 용도
EP4212536B1 (en) 2015-07-02 2025-02-19 F. Hoffmann-La Roche AG Benzoxazepin oxazolidinone compounds and methods of use
US20170362228A1 (en) * 2016-06-16 2017-12-21 Genentech, Inc. TETRAHYDRO-PYRIDO[3,4-b]INDOLE ESTROGEN RECEPTOR MODULATORS AND USES THEREOF
LT3810283T (lt) * 2018-06-21 2023-08-25 F. Hoffmann-La Roche Ag 3-((1r,3r)-1-(2,6-difluor-4-((1-(3-fluorpropil)azetidin-3- il)amino) fenil)-3-metil-1,3,4,9-tetrahidro-2h-pirido[3,4-b]indol-2-il)- 2,2- difluorpropan-1-olio tartrato druskos kietosios formos, jų paruošimo procesas ir jų naudojimo būdai vėžiui gydyti
KR20210035211A (ko) * 2018-07-23 2021-03-31 에프. 호프만-라 로슈 아게 Pi3k 저해제인 gdc-0077로 암을 치료하는 방법
CA3109090A1 (en) 2018-08-17 2020-02-20 F. Hoffmann-La Roche Ag Diagnostic and therapeutic methods for the treatment of breast cancer
CN115175679A (zh) * 2020-03-06 2022-10-11 奥列马制药公司 治疗雌激素受体相关疾病的方法

Also Published As

Publication number Publication date
TWI808648B (zh) 2023-07-11
ES3030540T3 (en) 2025-06-30
EP4294395B1 (en) 2025-03-26
TW202237100A (zh) 2022-10-01
WO2022177844A1 (en) 2022-08-25
JP2024506385A (ja) 2024-02-13
CN117377472A (zh) 2024-01-09
US20230381155A1 (en) 2023-11-30
EP4294395A1 (en) 2023-12-27
EP4294395C0 (en) 2025-03-26

Similar Documents

Publication Publication Date Title
IL280707B2 (en) Diagnostic and therapeutic methods for treating breast cancer
SI4181920T1 (sl) Inhibitor kat6 in kombinacije za zdravljenje raka dojke
IL281256A (en) Combined treatment for the treatment of triple-negative breast cancer
IL292197A (en) Leukemia treatment based on anti-cd47 and anti-cd20
IL279277A (en) In vivo controlled combination therapy for treatment of cancer
IL307465A (en) Combined therapies for cancer treatment
PL4294395T3 (pl) Leczenie raka sutka za pomocą terapii skojarzonych zawierających GDC-9545 i GDC-0077
IL308992A (en) Cancer treatment in patients with soluble FR-alpha
GB202018015D0 (en) Composition and methods for the treatment of intestinal cancer
LT4340842T (lt) Sotorasibas, skirtas naudoti vėžio gydymui
IL279591A (en) Cancer treatment methods using combination therapy
GB202107994D0 (en) Treatment of cancer
IL288178A (en) Combined gmci and ddri treatment for cancer
EP4157246B8 (en) Therapeutic combination for the treatment of breast cancer
IL275913A (en) Methods and combined treatment for cancer treatment
IL314687A (en) Cancer treatment
IL315250A (en) Combination therapies including GDC-6036 and GDC-0077 for the treatment of cancer
IL270306A (en) Prevention and treatment of pre-myeloid and myeloid malignancies
IL312899A (en) Combined treatment for cancer
IL300106A (en) Combination therapy for cancer treatment
GB202018062D0 (en) Treatment of cancer
GB202008037D0 (en) Treatment of cancer
GB202311976D0 (en) Treatment of cancer
GB202218181D0 (en) Treatment of cancer
HK40085109A (en) Combination therapy for treatment of cancer and cancer metastasis